DaVita Dialysis Center Loan

Submit your loan application for a Free Quote

Apply Now

DaVita Dialysis Center Loan:

This is one sample of a commerical real estate investmetn loan product available for DaVita Dialysis Center loan. The commercial real estate interest rates listed are as of September 16, 2020.

This is part of a national credit lease program which includes DaVita Dialysis Center Loans:

• Loans from $750,000 to $10,000,000 and up
• Multiple structures offered

Including 10 Year Fixed Interest Rate:
• Typical rates presently ranging from 3.79% to 3.99%
• Typical amortization: 25 years to 30 years
• Most require a minimum down payment between 20% and 25% of the purchase.
• Caffrey Loan Placement fee 1.0%
• Typical recourse: 20% to 25% Limited
• Flexible prepayment with extra 10% annual paydown allowed with no premium charged
• Minimum remaining primary lease term: 7 Years
• All loans assumable, with only ¼% fee
• Optional 50-day rate lock available
• Rate Lock—50 days from CCL acceptance and deposit submission
• Expedited closing process targets 33—35 days, CCL to potential closing table

This is a publically held company, DaVita (NYSE: DVA) is a health care provider focused on transforming care delivery to improve quality of life for patients globally. The company is one of the largest providers of kidney care services in the U.S. and has been a leader in clinical quality and innovation for more than 20 years. Through DaVita Kidney Care, the company treats patients with chronic kidney failure and end stage kidney disease. DaVita is committed to bold, patient-centric care models, implementing the latest technologies and moving toward integrated care offerings for all. Through these efforts, DaVita has also become the largest provider of home dialysis in the country. As of December 31, 2019, DaVita served 206,900 patients at 2,753 outpatient dialysis centers in the United States. The company also operated 259 outpatient dialysis centers in ten countries worldwide. This tenant has reduced hospitalizations, improved mortality, and worked collaboratively to propel the kidney care industry to adopt an equitable and high-quality standard of care for all patients, everywhere.

Here is the link to DaVita’s Financial Reports.

Recent financial developments:

DENVER, CO, September 17, 2020 – DAVITA INC. (NYSE: DVA) (“DaVita”) a health care provider focused on transforming care delivery to improve quality of life for patients globally and one of the largest providers of kidney care services in the United States, announced today the final results of its modified “Dutch auction” tender offer for up to $1.0 billion of its common stock at a price per share not less than $77.00 and not more than $88.00, which expired at 12:00 midnight, New York City time, at the end of the day on September 14, 2020.

Based on the final count by the depositary for the tender offer, a total of 7,981,679 shares of DaVita’s common stock were validly tendered and not validly withdrawn at or below the price of $88.00 per share. The company accepted all of these shares for purchase at a purchase price of $88.00 per share, for a total cost of $702,387,752, excluding fees and expenses related to the tender offer. The total of 7,981,679 shares accepted for payment represents approximately 6.5% of DaVita’s total outstanding common stock as of September 16, 2020. The depositary for the tender offer will promptly pay for the shares accepted for purchase pursuant to the tender offer. Payment for shares purchased will be made in cash, without interest, but subject to applicable withholding taxes.

The comapny/DaVita will finance the share purchases in the tender offer with cash on hand.

Public Credit Ratings for DaVita:

Moody’s Investors Service, Inc. shows the following credit rating for DaVita, Inc. of Ba2. This was pulled from Moody’s on September 17, 2020, rating was last affirmed July 22, 2019, not on watchlist, Outlook was Stable. You should be aware a Moody’s Ba2 Credit Rating is not considered Investment Grade.

Standard & Poor’s Credit Rating for DaVita Dialysis is BB when checked on September 17, 2020. This rating was last reviewed by S&P on September 12, 2020, placed on negative Watch. In conclusion a S&P rating of BB is not considered Investment Grade.

You can find a credit rating chart on this link for both Moody’s and Standard and Poors:  Credit Rating Charts
Caffrey & Company LLC is your source for commercial real estate loans. Please see our current rates for this type of property and other properties at Rates: We have many loan products to choose from. We are part of two nationwide professional networks www.cfbncre.com and www.inter-capital.com. Send us your transaction details for a free loan quote.

Caffrey & Company LLC contact Mike Caffrey Landline: (913) 402-7077 or email: [email protected]

On our web site you can read about specific loan products: www.caffreyloans.com/loan-products, offered by Freddie Mac, Fannie Mae, HUD/FHA, Commercial Mortgage Back Securities (CMBS) and other loan products. Want more details on sample interest rates for apartment check out Interest Rates for Apartment Loans also on our web site: www.caffreyloans.com/apartment-loans.

Have a question please contact
Mike Caffrey
Telephone: (913) 402-7077
[email protected]